Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the Groupe d'Etudes des Lymphomes de l'Adulte

Blood

Volumn 116, Issue 12, 2010, Pages 2040-2045

  Coiffier, Bertrand ^a   Thieblemont, Catherine ^b   Van Den Neste, Eric ^c   Lepeu, Gérard ^d   Plantier, Isabelle ^e   Castaigne, Sylvie ^f   Lefort, Sophie ^g   Marit, Gérald ^h   Macro, Margaret ⁱ   Sebban, Catherine ^j   Belhadj, Karim ^k   Bordessoule, Dominique ^l   Fermé, Christophe ^m   Tilly, Hervé ⁿ  

^a UNIVERSITÉ LYON 1   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d CENTRE HOSPITALIER D AVIGNON   (France)

^e Hopital Victor Provo   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g CENTRE HOSPITALIER   (France)

^h HAUT LÉVÊQUE HOSPITAL   (France)

ⁱ CHU CÔTE DE NACRE   (France)

^j CENTRE LÉON BÉRARD   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l DUPUYTREN UNIVERSITY HOSPITAL   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ CENTRE HENRI BECQUEREL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; DRUG TOLERABILITY; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SECOND CANCER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; LONGITUDINAL STUDY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TOXICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAUSE OF DEATH; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LONGITUDINAL STUDIES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 77957200763     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-276246     Document Type: Article

References (15)

1. Coiffier B. State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2005;23(26):6387-6393.
2. Coiffier B, Lepage E, Herbrecht R, et al. Mab-Thera (rituximab) plus CHOP is superior to CHOP alone in elderly patients with diffuse large B-cell lymphoma (DLCL): Interim results of a randomized GELA trial [abstract]. Blood. 2000;96 (suppl): Abstract 950.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
4. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117-4126. (Pubitemid 46211317)
5. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105-116.
6. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
7. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121-3127. (Pubitemid 46638950)
8. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417-1423. (Pubitemid 40223656)
9. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10):3064-3071.
10. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France; IARC; 2001.
11. Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-hodgkins lymphoma. N Engl J Med. 1993;329(14):987-994.
12. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17(4):1244-1253.
13. Larouche J, Berger F, Chassagne-Clément C, et al. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: Clinical characteristics and outcome. J Clin Oncol. 2010;28(12):2094-2100.
14. The NHLClassification Project. Effect of Age On the Characteristics and Clinical Behavior of Non-Hodgkins Lymphoma Patients. Ann Oncol. 1997;8(10):973-978.
15. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era: a CORAL study [published online ahead of print July 26, 2010]. J Clin Oncol. doi:1.1200/JCO.201.28.1618.